Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
PROMETEO is a window opportunity, single arm, exploratory study to evaluate the effect of T-
VEC combined with Atezolizumab in women with operable early breast cancer who present
residual disease after Neoadjuvant Chemotherapy (NAC). Other eligibility criteria include
TNBC or LumB like primary tumor sized at least 1.5 cm, ECOG PS 0-1 and evaluable diagnostic
tumor sample.